Abstract
Drug regulators' acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.
Original language | English (US) |
---|---|
Pages (from-to) | 399-400 |
Number of pages | 2 |
Journal | Nature Reviews Clinical Oncology |
Volume | 15 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2018 |
ASJC Scopus subject areas
- Oncology